Skip to content

Pinguecula treatment

Recurrence of pinguecula by ligation and subconjunctival bevacizumab (avastin) injection in short time

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240702062306N1
Enrollment
20
Registered
2024-07-23
Start date
2020-11-05
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pinguecula.

Interventions

Intervention group: After all the patients underwent ligation and were divided into two intervention and control groups. In both groups, Pinguecula base ligation was performed, but only in the interve

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patient with pinguecula withouth xerophthalmia and eye surgery withouth diabetes and pregnancy and allergy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The size of the horizontal surface of Pinguecula. Timepoint: Before the start of the study/one week/one month/3 months and six months after ligation and bevacizumab injection. Method of measurement: Quantitative measurement by slit lamp device and its qualitative grading.

Secondary

MeasureTime frame
The degree of inflammation and hyperemia. Timepoint: Before the start of the study/one week/one month/3 months and six months after ligation and bevacizumab injection. Method of measurement: Quantitative measurement by slit lamp device and its qualitative grading.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohadese Sarabadani

Mazandaran University of Medical Sciences

M.sarabadi@gmail.com+98 21 4425 8200

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026